Analysts Set Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) PT at $22.00

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been given a consensus rating of “Reduce” by the eight research firms that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $22.00.

Several equities analysts have weighed in on the company. Bank of America restated an “underperform” rating and set a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Piper Sandler reiterated a “neutral” rating and set a $21.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Wells Fargo & Company reissued an “equal weight” rating and set a $19.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $19.75 on Friday. The company’s fifty day moving average is $19.17 and its 200-day moving average is $22.14. Amphastar Pharmaceuticals has a 12 month low of $16.65 and a 12 month high of $31.26. The firm has a market cap of $870.78 million, a price-to-earnings ratio of 11.90, a price-to-earnings-growth ratio of 3.88 and a beta of 0.89. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The business had revenue of $171.17 million for the quarter, compared to the consensus estimate of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. Equities analysts expect that Amphastar Pharmaceuticals will post 2.41 EPS for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at $26,000. Quarry LP bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth $32,000. Farther Finance Advisors LLC lifted its position in Amphastar Pharmaceuticals by 46.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after acquiring an additional 437 shares during the last quarter. GAMMA Investing LLC lifted its position in Amphastar Pharmaceuticals by 37.8% during the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock worth $45,000 after acquiring an additional 462 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Amphastar Pharmaceuticals by 24.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.